Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit
Protagonist Therapeutics (Nasdaq: PTGX) announced that Dr. Dinesh V. Patel, President and CEO, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit from December 6-7, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protagonist Therapeutics (Nasdaq: PTGX) announced that Dr. Dinesh V. Patel, President and CEO, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit from December 6-7, 2022. The chat is scheduled for December 6, 2022, at 11:40 a.m. ET. A webcast will be accessible for 90 days on Protagonist's Investors section. The company is advancing its lead drug candidate, rusfertide, in a global Phase 3 study for polycythemia vera, and has partnered with Janssen Biotech on PN-235 for psoriasis and inflammatory bowel disease.
Details
News Market Reaction – PTGX
The recorded move for PTGX in the trading session of this news was -1.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWARK, Calif., Dec. 1, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation and host one-on-one meetings with investors at the JMP Securities Hematology and Oncology Summit, a virtual investor event taking place December 6-7, 2022.
Date: December 6, 2022
Time: 11:40 a.m. ET / 8:40 a.m. PT
A webcast of the event will be available for 90 days on the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and PN-235 in advanced stages of clinical development, both derived from the Company's proprietary technology platform. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 stage of development. The VERIFY (Phase 3) and REVIVE (Phase 2) studies of rusfertide in polycythemia vera are ongoing. Protagonist owns all marketing rights to rusfertide.
Protagonist has partnered with Janssen Biotech, Inc. on the development of PN-235 (JNJ-77242113) in moderate-to-severe psoriasis and inflammatory bowel disease. PN-235 is currently in multiple studies in psoriasis, led by Janssen.
Protagonist is headquartered in Newark, California. For more information on Protagonist, please visit the Company's website at www.protagonist-inc.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-jmp-securities-hematology-and-oncology-summit-301691132.html
SOURCE Protagonist Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.